AYTU Aytu Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: AYTU
Price (delayed)
$2.37
Market cap
$14.62M
P/E Ratio
11.85
Dividend/share
N/A
EPS
$0.2
Enterprise value
$17.87M
Highlights
The company's net income has surged by 131% QoQ and by 112% YoY
AYTU's EPS has soared by 121% QoQ and by 108% YoY
The gross profit has contracted by 16% YoY but it has grown by 5% from the previous quarter
AYTU's revenue is down by 15% YoY but it is up by 7% QoQ
The company's debt rose by 35% QoQ and by 28% YoY
Key stats
What are the main financial stats of AYTU
Market
Valuations
Earnings
Shares outstanding
6.17M
Market cap
$14.62M
Enterprise value
$17.87M
Price to earnings (P/E)
11.85
Price to book (P/B)
0.42
Price to sales (P/S)
0.21
EV/EBIT
1.77
EV/EBITDA
1.11
EV/Sales
0.26
Revenue
$69.22M
Gross profit
$47.48M
Operating income
-$3.85M
Net income
$1.64M
EBIT
$10.1M
EBITDA
$16.13M
Free cash flow
-$5.07M
Per share
Balance sheet
Liquidity
EPS
$0.2
EPS diluted
-$1.02
Free cash flow per share
-$0.83
Book value per share
$5.66
Revenue per share
$11.28
TBVPS
$12.31
Total assets
$124.2M
Total liabilities
$89.3M
Debt
$21.42M
Equity
$34.9M
Working capital
$1.81M
Debt to equity
0.61
Current ratio
1.03
Quick ratio
0.76
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
23.3%
Gross margin
68.6%
Net margin
2.4%
Operating margin
-5.6%
Return on assets
1.4%
Return on equity
5.3%
Return on invested capital
993.5%
Return on capital employed
18.9%
Return on sales
14.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AYTU stock price
How has the Aytu Biopharma stock price performed over time
Intraday
0%
1 week
-1.25%
1 month
1.28%
1 year
-1.66%
YTD
39.41%
QTD
8.72%
Financial performance
How have Aytu Biopharma's revenue and profit performed over time
Revenue
$69.22M
Gross profit
$47.48M
Operating income
-$3.85M
Net income
$1.64M
Gross margin
68.6%
Net margin
2.4%
The company's net income has surged by 131% QoQ and by 112% YoY
The company's net margin has surged by 130% QoQ and by 114% YoY
Aytu Biopharma's operating margin has surged by 54% QoQ
Aytu Biopharma's operating income has soared by 51% from the previous quarter
Price vs fundamentals
How does AYTU's price correlate with its fundamentals
Growth
What is Aytu Biopharma's growth rate over time
Valuation
What is Aytu Biopharma stock price valuation
P/E
11.85
P/B
0.42
P/S
0.21
EV/EBIT
1.77
EV/EBITDA
1.11
EV/Sales
0.26
AYTU's EPS has soared by 121% QoQ and by 108% YoY
The P/B is 16% below the 5-year quarterly average of 0.5 but 5% above the last 4 quarters average of 0.4
Aytu Biopharma's equity has increased by 13% QoQ and by 13% YoY
AYTU's P/S is 70% below its 5-year quarterly average of 0.7 but 5% above its last 4 quarters average of 0.2
AYTU's revenue is down by 15% YoY but it is up by 7% QoQ
Efficiency
How efficient is Aytu Biopharma business performance
The ROA has soared by 132% from the previous quarter and by 114% YoY
The ROE has soared by 130% from the previous quarter and by 113% YoY
AYTU's ROS has soared by 125% QoQ
Dividends
What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AYTU.
Financial health
How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 39% higher than its total liabilities
Aytu Biopharma's quick ratio has increased by 29% YoY and by 6% from the previous quarter
AYTU's current ratio is up by 21% YoY and by 5% from the previous quarter
The company's debt is 39% lower than its equity
The company's debt rose by 35% QoQ and by 28% YoY
The debt to equity has grown by 17% from the previous quarter and by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.